Tiova Rotacap: Advanced Bronchodilation for COPD Management
| Product dosage: 18 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $1.51 | $45.18 (0%) | 🛒 Add to cart |
| 60 | $1.31 | $90.36 $78.31 (13%) | 🛒 Add to cart |
| 90 | $0.96
Best per cap | $135.54 $86.34 (36%) | 🛒 Add to cart |
Synonyms | |||
Tiova Rotacap is a high-efficacy, long-acting muscarinic antagonist (LAMA) inhalational therapy designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It contains Tiotropium Bromide as its active pharmaceutical ingredient, which works by selectively inhibiting muscarinic receptors in the bronchial smooth muscles, resulting in sustained bronchodilation. This formulation is delivered via a Rotahaler device, ensuring deep lung deposition and consistent dosing. It is indicated for once-daily use to improve lung function, reduce exacerbations, and enhance overall quality of life in patients with COPD, including chronic bronchitis and emphysema. Clinical evidence supports its role in providing 24-hour symptom control with a favorable safety profile.
Features
- Contains Tiotropium Bromide 18 mcg per capsule
- Delivered via breath-activated Rotahaler device for optimal pulmonary deposition
- Once-daily dosing regimen for improved adherence
- Dry powder inhaler (DPI) format, no propellants required
- Pre-measured single-dose capsules for accuracy and convenience
- Stable at room temperature; does not require refrigeration
- Manufactured under strict pharmaceutical quality control standards
Benefits
- Provides sustained 24-hour bronchodilation, reducing the frequency of rescue inhaler use
- Improves lung function parameters (FEV1) and exercise tolerance
- Lowers the risk of COPD exacerbations and related hospitalizations
- Enhances overall quality of life through better symptom control and reduced breathlessness
- Supports long-term disease management with a simple once-daily regimen
- Minimizes systemic side effects due to localized action in the lungs
Common use
Tiova Rotacap is primarily prescribed for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not intended for immediate relief of acute bronchospasm. The medication is used as a long-term control agent to improve airflow, reduce dynamic hyperinflation, and prevent exacerbations. It may be used as monotherapy or in combination with other maintenance bronchodilators, such as long-acting beta-agonists (LABAs) or inhaled corticosteroids (ICS), depending on disease severity and treatment goals.
Dosage and direction
The recommended dosage for Tiova Rotacap is the inhalation of the contents of one capsule (18 mcg) once daily, at the same time each day. Administration should be performed using the Rotahaler device. To use: open the Rotahaler, place the capsule in the chamber, close the device, then pierce the capsule by pressing the side buttons firmly. Breathe out fully away from the device, place the mouthpiece between lips, and inhale deeply and steadily. Hold breath for up to 10 seconds if possible, then exhale slowly. Do not exhale into the device. The capsule should be completely empty after use. Do not swallow the capsule.
Precautions
- Not for use in the treatment of acute bronchospasm; always keep a fast-acting rescue inhaler available.
- Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction, due to anticholinergic effects.
- Monitor for signs of paradoxical bronchospasm; discontinue immediately if it occurs.
- Avoid getting powder in the eyes, as it may cause blurred vision or pupil dilation.
- Patients with severe renal impairment (CrCl < 30 mL/min) should be monitored closely.
- Not recommended for use in children or adolescents under 18 years of age.
- Inform healthcare provider of all current medications to avoid potential interactions.
Contraindications
Tiova Rotacap is contraindicated in patients with a known hypersensitivity to Tiotropium Bromide, atropine or its derivatives, or any other component of the formulation. It is also contraindicated in patients with a history of severe hypersensitivity reactions to milk proteins (as the capsule may contain lactose).
Possible side effect
Common side effects may include dry mouth, sinusitis, pharyngitis, dyspepsia, abdominal pain, constipation, and urinary retention. Less frequently, patients may experience tachycardia, palpitations, blurred vision, glaucoma, difficulty in micturition, cough, hoarseness, and dizziness. Allergic reactions such as skin rash, itching, angioedema, and anaphylaxis are rare but possible. Paradoxical bronchospasm may occur immediately after inhalation and requires discontinuation.
Drug interaction
Tiotropium Bromide may interact with other anticholinergic agents (e.g., ipratropium, aclidinium), potentially increasing the risk of side effects such as dry mouth, urinary retention, or glaucoma. Concomitant use with beta-adrenergic drugs may have additive bronchodilatory effects. Caution is advised when using with drugs that are excreted renally or that may affect renal function. No clinically significant pharmacokinetic interactions have been observed with cytochrome P450 substrates.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. However, if it is nearly time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Maintaining a consistent daily routine is important for optimal therapeutic effect.
Overdose
Overdose may lead to exaggerated anticholinergic effects such as severe dry mouth, visual disturbances, tachycardia, urinary retention, and constipation. In case of suspected overdose, discontinue the medication and provide supportive care. Treatment is symptomatic; activated charcoal may be administered if ingestion occurs. Dialysis is not effective due to high protein binding and extensive tissue distribution. Seek immediate medical attention.
Storage
Store below 30°C, in a dry place, protected from light and moisture. Keep the capsules in the original blister pack until immediately before use. Do not expose to extreme temperatures or humidity. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Individual patient responses may vary. The manufacturer and distributor are not liable for any inaccuracies or misuse of the product.
Reviews
Clinical studies and patient reports consistently highlight the efficacy of Tiova Rotacap in improving lung function and reducing exacerbation frequency in COPD patients. Many users report better day-to-day breathing, increased activity tolerance, and greater convenience due to once-daily dosing. Some note initial dry mouth or throat irritation, which often subsides with continued use. Overall, it is regarded as a reliable and well-tolerated option for long-term COPD management.